$1.61
-0.03 (-1.83%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MDAI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 2 tracked-famous managers (MARSHALL WACE, LLP, JANE STREET GROUP, LLC) · FINRA short interest 14.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker DetectionNCT07446582observationalAssessment of equivalency in sensitivity and specificity of the DeepMSI AI system compared with experienced clinicians for detection of AMD biomarkers. | — | Recruiting | Device: Retina imaging device (MSI-120) and AI (DeepMSI AI) | Age-Related (Dry) Macular Degeneration | 1,000 | 2026-09-05 | in 17 d | 2026-03-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19